VPC
AXSM icon

Vestal Point Capital’s Axsome Therapeutics AXSM Stock Holding History

Vestal Point Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-210,000
Closed -$38.4M – 94
2025
Q4 		$38.4M Buy
210,000
+60,000
+40% +$8.38M 1.3% 25
2025
Q3 		$18.2M Buy
+150,000
New +$16.9M 0.82% 43
2024
Q3 		– Sell
-300,000
Closed -$24.1M – 72
2024
Q2 		$24.1M Buy
+300,000
New +$22.2M 1.8% 18

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vestal Point Capital's AXSM Position: Q1 2026 in Review

Vestal Point Capital sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 210,000 shares — an estimated $38.4M sold.

Vestal Point Capital first reported a position in AXSM in Q2 2024 and held it in 3 quarters. The position peaked at $38.4M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Vestal Point Capital reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vestal Point Capital sold 210,000 Axsome Therapeutics shares in Q1 2026, an estimated $38.4M.
  • Vestal Point Capital first reported a position in Axsome Therapeutics in Q2 2024 and held it in 3 quarters.
  • Vestal Point Capital's Axsome Therapeutics position peaked at $38.4M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.